目次

1. Combination Cancer Immunotherapy - New Era in Cancer Research

2. Need for Combination Cancer Immunotherapy

3. Clinically and Commercially Approved Combination Cancer Immunotherapy

4. Global Combination Cancer Immunotherapy Market Size and Trend Analysis
4.1 Current Market Scenario
4.2 Future Market Opportunity

5. Global Combination Cancer Immunotherapy Market Size and Trend Analysis by Indication
5.1 Breast Cancer
5.2 Kidney Cancer
5.3 Lung Cancer
5.4 Liver Cancer
5.5 Gastric Cancer
5.6 Lymphoma
5.7 Prostate Cancer
5.8 Melanoma
5.9 Colorectal Cancer
5.10 Leukemia
5.11 Cervical Cancer
5.12 Pancreatic Cancer
5.13 Ovarian Cancer
5.14 Head and Neck Cancer
5.15 Multiple Myeloma

6. Global Combination Cancer Immunotherapy Market Size and Trend Analysis by Region
6.1 US
6.2 Europe
6.3 China
6.4 Japan
6.5 Australia
6.6 South Korea
6.7 Canada
6.8 UK

7. Approved Immune Checkpoint Inhibitor In Combination Cancer Immunotherapy - Clinical and Commercial Insights
7.1 Patent, Price and Dosage Analysis
7.2 Global and Regional Sales Insights

8. Approved Antibody Drug Conjugate In Combination Cancer Immunotherapy - Clinical and Commercial Insights
8.1 Patent, Price and Dosage Analysis
8.2 Global and Regional Sales Insights

9. Approved Monoclonal Antibodies In Combination Cancer Immunotherapy - Clinical and Commercial Insights
9.1 Patent, Price and Dosage Analysis
9.2 Global and Regional Sales Insights

10. Combination Cancer Immunotherapy Clinical Trials Overview
10.1 By Company
10.2 By Country
10.3 By Patient Segment/Disease Stage
10.4 By Phase

11. Combination Cancer Immunotherapy Clinical Trials and Patent Insight By Company, Country, Indication and Phase
11.1 Research
11.2 Preclinical
11.3 Clinical
11.4 Phase-I
11.5 Phase-I/II
11.6 Phase-II
11.7 Phase-II/III
11.8 Phase-III
11.9 Preregistration
11.10 Registered

12. Marketed Combination Cancer Immunotherapy Clinical and Patent Insight By Company, Country, and Indication

13. Combination Strategies to Enhance Immune Checkpoint Inhibitors Efficacy
13.1 In Combination with Other Immune Checkpoint Blockade:
13.2 Ongoing Clinical Trials of ICI with Conventional Therapies; Chemotherapy and Radiation
13.3 ICI Trials with Other Targeted Therapies
13.4 Recent Trends in Market: Partnerships, Collaboration, and Investments

14. Combination of Therapeutic Antibodies in Clinical Oncology
14.1 Combination Trials of Monoclonal Antibodies
14.2 Clinical Trials of Bispecific Antibody Combination Therapy
14.3 Pharmaceutical Investments Boosting Market

15. Engaging Cancer Vaccines in Combination Therapy
15.1 Preclinical Studies Evaluating Vaccines in Combination Therapy
15.2 Clinical Trials Evaluating Cancer Vaccines in Combination Approach
15.3 Ongoing Research Agreement and Collaboration

16. Antibody Drug Conjugate in Combination Therapy
16.1 Ongoing Clinical Investigations
16.2 Pharmaceutical Collaborations and Supply Agreements

17. Combination Therapy with CAR T Cell Therapy
17.1 Preclinical Studies Combining CAR T cell Therapy
17.2 Clinical Trials Evaluating Combination Therapies with CAR T Cells
17.3 Ongoing Research and Development Activities

18. Oncolytic Virus Combination Therapy
18.1 OV Combination Immunotherapy
18.2 Oncolytic Virus in Combination with Other Regimens
18.3 Recent Trends in Market: Partnerships, Collaboration, and Investments

19. Competitive Landscape
19.1 AbbVie
19.2 Agenus
19.3 Akeso Pharmaceutical
19.4 Amgen
19.5 Arbutus Biopharma
19.6 AstraZeneca
19.7 AUM Bioscience
19.8 BeiGene
19.9 BioNTech
19.10 Bristol Myers Squibb
19.11 Candel Therapeutics
19.12 Eli Lilly
19.13 Elicio Therapeutics
19.14 Fate Therapeutics
19.15 GlaxoSmithKline
19.16 Harpoon Therapeutics
19.17 Immutep
19.18 Imugene
19.19 Intensity Therapeutics
19.20 Janssen Pharmaceuticals
19.21 Merck
19.22 MorphoSys
19.23 Novocure
19.24 Novartis
19.25 Nykode Therapeutics
19.26 Ono Pharmaceutical
19.27 Oxford Biotherapeutics
19.28 Pfizer
19.29 Regeneron?
19.30 Roche
19.31 Sanofi
19.32 Seagen
19.33 Shanghai Junshi Biosciences
19.34 Takeda Pharmaceuticals
19.35 Qurient